Bausch Health Cos (NYSE:BHC) Shares Up 4% - Here's What Happened

Key Points

• Bausch Health Cos shares rose by 4% on Wednesday, closing at $6.41, with trading volume significantly down at 179,105 shares compared to an average of over 2.4 million.
• Analysts have given the stock a consensus rating of "Hold" with a target price of $9.00, indicating mixed sentiments regarding its future performance.
• Insider John Paulson significantly increased his stake by purchasing over 34 million shares, reflecting strong confidence in the company's potential for growth.

Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) shot up 4% on Wednesday . The stock traded as high as $6.43 and last traded at $6.41. 179,105 shares traded hands during trading, a decline of 93% from the average session volume of 2,492,434 shares. The stock had previously closed at $6.16.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BHC. Weiss Ratings reissued a "hold (c)" rating on shares of Bausch Health Cos in a report on Wednesday, October 8th. Wall Street Zen cut Bausch Health Cos from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 11th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $9.00.

Bausch Health Cos Trading Up 2.2%

The stock has a fifty day moving average of $6.92 and a 200 day moving average of $6.02. The company has a market capitalization of $2.33 billion, a P/E ratio of 24.21 and a beta of 0.43. The company has a debt-to-equity ratio of 141.90, a quick ratio of 0.98 and a current ratio of 1.31.

Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.The company had revenue of $2.57 billion during the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Bausch Health Cos Inc. will post 4.41 EPS for the current fiscal year.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, Director John Paulson purchased 34,721,118 shares of the business's stock in a transaction on Thursday, August 14th. The stock was acquired at an average price of $9.00 per share, for a total transaction of $312,490,062.00. Following the purchase, the director owned 70,755,869 shares of the company's stock, valued at approximately $636,802,821. This represents a 96.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders acquired 37,964,167 shares of company stock valued at $333,757,793. Corporate insiders own 19.97% of the company's stock.

Institutional Investors Weigh In On Bausch Health Cos

A number of institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new position in shares of Bausch Health Cos during the first quarter valued at about $27,000. Cary Street Partners Financial LLC purchased a new position in shares of Bausch Health Cos during the first quarter valued at about $27,000. SBI Securities Co. Ltd. grew its position in shares of Bausch Health Cos by 244.2% during the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after purchasing an additional 3,001 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company's stock valued at $51,000 after purchasing an additional 3,106 shares in the last quarter. Finally, Wealthquest Corp purchased a new position in shares of Bausch Health Cos during the first quarter valued at about $58,000. Hedge funds and other institutional investors own 78.65% of the company's stock.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.